<DOC>
	<DOCNO>NCT00408499</DOCNO>
	<brief_summary>RATIONALE : Erlotinib may stop growth tumor cell block enzymes need cell growth . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving erlotinib together cetuximab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose erlotinib cetuximab see well work treat patient advance solid tumor progressive recurrent stage III stage IV non-small cell lung cancer .</brief_summary>
	<brief_title>Erlotinib Cetuximab Treating Patients With Advanced Solid Tumors With Emphasis Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety feasibility erlotinib hydrochloride cetuximab patient advance solid tumor . ( Phase I ) - Determine efficacy regimen , term objective tumor response rate , patient advance non-small cell lung cancer ( NSCLC ) pre-treated platinum . ( Phase II ) Secondary - Determine maximum tolerate dose regimen patient . ( Phase I ) - Determine efficacy regimen , term response rate , patient . ( Phase I ) - Determine progression-free overall survival patient treat regimen . ( Phase II ) - Determine frequency severity toxicity regimen patient . ( Phase II ) - Determine epidermal growth factor receptor ( EGFR ) K-RAS mutation status . ( Phase II ) - Evaluate EGFR protein expression protein expression downstream marker ( e.g. , pMAPK , pAKT , p27 , Ki-67 ) . ( Phase II ) - Evaluate level marker protein ( e.g. , pMAPK , pAKT , p27 , Ki-67 ) buccal cell . ( Phase II ) - Determine gene copy number EGFR fluorescent situ hybridization ( FISH ) . ( Phase II ) - Identify EGFR polymorphism analysis genomic DNA peripheral blood mononuclear cell . ( Phase II ) - Determine continue presence absence mutant K-RAS tumor DNA correlate response and/or outcome . ( Phase II ) OUTLINE : This phase I , dose-escalation study follow open-label , phase II study . - Phase I : Patients receive oral erlotinib hydrochloride daily day 1-28 cetuximab IV 1-2 hour day 1 , 8 , 15 , 22 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos erlotinib hydrochloride cetuximab maximum tolerate dose ( MTD ) determine . The MTD define dose precede â‰¥ 2 6 patient experience dose-limiting toxicity . At least 6 patient treated MTD . - Phase II : Patients receive erlotinib hydrochloride cetuximab MTD determine phase I . Blood buccal sample acquire patient baseline prior course 2 3 . Samples examine fluorescent situ hybridization ( FISH ) , immunohistochemistry , polymorphism analysis , protein expression assay ass molecular marker ( epidermal growth factor receptor , K-RAS , pMAPK , pAKT , p27 Ki-67 ) biologic effect predictive response . After completion phase I treatment , patient follow 30 day toxicity resolve . After completion phase II treatment , patient follow periodically . PROJECTED ACCRUAL : A total 62 patient accrue study</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Inclusion criterion For phase I portion study ( complete 10/05/08 ) , patient must cytologically histologically proven advanced solid tumor standard effective therapy available . Any number prior chemotherapy regimen allow Phase I Phase II portion For phase II portion patient must cytologically histologically proven select stage IIIB ( pleural effusion ) IV NSCLC . Patients NSCLC progress recurred firstline therapy stage IIIA IIIB may also consider . Patients must measurable disease RECIST criterion Phase II portion . Disease previously irradiate site consider measurable clear disease progression follow radiation therapy . Patients evaluable disease ( bone metastasis , pleural fluid , ascites , etc . ) may include phase I portion trial ( complete 10/08/08 ) . Must 18 year age old . Patients must performance status 0 2 . Patients must estimate survival least 3 month . Any prior chemotherapy must complete least 4 week prior start treatment . For prior mitomycin chemotherapy 6week interval require . Prior radiation must complete least 2 week prior start therapy . Patients must recover acute reversible medically significant side effect prior chemotherapy regimen radiotherapy NCICTC &lt; grade 1 ( exclude alopecia ) . Prior herceptin allow . Patients must adequate renal function document serum creatinine &lt; 1.5 mg/dl calculate creatinine clearance &gt; 45 ml/min ( see protocol Appendix D formula calculate creatinine clearance ) . Patients must adequate liver function document serum bilirubin &lt; 1.5 x ULN . AST must &lt; 2.5 x institutional upper limit normal . Patients must pretreatment granulocyte count &gt; 1500/mm3 platelet count &gt; 100 000/mm3 . Patients asymptomatic treat brain metastasis ( surgical resection radiotherapy ) may include neurologically stable steroid anticonvulsant least 2 week . All patient must give voluntary write informed consent . Patients must able take retain oral medication . Documentation negative serum pregnancy test . Patients coumadin INR monitor least per week frequently depend investigator 's judgment . There case report increase INR coumadin coadministered erlotinib . Exclusion criterion Patients receive erlotinib , cetuximab , EGFRdirected therapy ( exclude herceptin ) . Patients symptomatic brain metastasis still require steroid anticonvulsant may include . For phase II portion study , prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree five year Patients acute hepatitis know HIV . Patients active uncontrolled infection . Patients significant history uncontrolled cardiac disease ; i.e. , uncontrolled hypertension , unstable angina , recent myocardial infarction ( within prior 6 month ) , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction . Patients prior severe infusion reaction monoclonal antibody . Any concurrent chemotherapy indicate study protocol investigational agent ( ) . Pregnant breastfeeding female effect drug unborn fetus unknown .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>